EGFR and Hypertension: The most frequent treatment-related grade ≥ 2 adverse events likely related to the EGFR inhibition by cetuximab and erlotinib were: rash (56%), hypomagnesemia (17%), pruritus (11%), diarrhea (8%) and likely related to antiangiogenic effect of bevacizumab were: hypertension, bleeding, and fistula (Table 2).